Is it safe to get Wegovy online?

Last Updated: December 17, 2025

If you’re considering GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss, you’ve probably wondered: Can I get these prescribed through telehealth, or do I need to visit a doctor’s office in person?

The short answer is yes—in most cases, you can legally obtain these weight-loss medications through telehealth appointments. But the details matter, especially when it comes to your specific state’s regulations, provider qualifications, and what to expect from a legitimate telehealth service.

This comprehensive guide breaks down everything you need to know about accessing GLP-1 weight-loss medications via telemedicine, including federal rules, state-by-state requirements, and how to identify safe, compliant telehealth providers.

Understanding Federal Telehealth Rules for Weight-Loss Medications

The Good News: GLP-1 Medications Are Not Controlled Substances

Unlike stimulant medications used for ADHD (such as Adderall) or certain pain medications, Wegovy, Ozempic, and Mounjaro are not controlled substances under federal law. This distinction is crucial because it means these medications are not subject to the Ryan Haight Act, which historically required an in-person medical examination before prescribing controlled substances via telemedicine.

Since GLP-1 agonists fall outside this restriction, federal law does not mandate an in-person visit before a licensed healthcare provider can prescribe them through telehealth. This creates a pathway for millions of Americans to access evidence-based obesity treatment from the comfort of their homes.

COVID-Era Flexibilities and What They Mean Today

During the COVID-19 pandemic, the Drug Enforcement Administration (DEA) temporarily waived in-person requirements for all telehealth prescribing, including controlled medications. While those pandemic-era flexibilities were initially set to expire, the DEA has repeatedly extended them—most recently through December 31, 2025.

However, it’s important to note: this extension primarily affects controlled substances like ADHD medications and certain addiction treatment drugs. For GLP-1 weight-loss medications, telehealth prescribing has been—and remains—fully permitted under federal law, with or without these temporary waivers.

What Happens in 2026?

Federal regulators are working on permanent telehealth prescribing rules. Congress has introduced legislation like the TREATS Act to make certain telehealth flexibilities permanent, particularly for mental health and substance use disorder treatment. While these efforts focus on controlled medications, they reflect a broader governmental commitment to expanding telehealth access.

For patients seeking GLP-1 medications, the regulatory outlook is stable: telehealth access to these drugs is not threatened by potential changes to controlled substance rules.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-by-State Telehealth Requirements: What You Need to Know

While federal law allows telehealth prescribing of GLP-1 medications, state regulations add an extra layer of requirements. Some states have specific rules about initial examinations, follow-up visits, lab work, and which types of providers can prescribe these drugs.

Here’s what varies by state:

In-Person Examination Requirements

Some states require an initial in-person physical examination before a provider can prescribe weight-loss medications via telehealth. Others allow the entire treatment process—from initial evaluation through ongoing monitoring—to occur virtually.

States requiring initial in-person exams:

• Arkansas
• Delaware
• Georgia
• Mississippi
• New Jersey (with comprehensive labs)
• North Dakota
• South Carolina
• Texas
• Utah
• Virginia (with labs and diet/exercise plan)

States allowing fully virtual care:

• California
• Connecticut
• Illinois
• New York
• Pennsylvania
• Washington

Follow-Up and Monitoring Requirements

Beyond the initial consultation, several states mandate regular follow-up visits to ensure patient safety:

• Florida: Requires at least one follow-up visit every 3 months during active treatment
• Virginia: Mandates a follow-up within 30 days of starting therapy
• Connecticut: Requires ongoing behavioral counseling and diet/exercise planning as part of treatment

These requirements reflect best practices in obesity medicine—GLP-1 medications work best when combined with lifestyle modifications and medical monitoring for side effects.

Provider Type Restrictions

Who can prescribe these medications varies significantly by state:

States with independent Nurse Practitioner (NP) practice:

• California, New York, Washington, Connecticut, Utah allow NPs to prescribe independently after meeting experience requirements

States requiring physician collaboration:

• Texas, Florida, Pennsylvania require NPs and Physician Assistants (PAs) to have formal agreements with supervising physicians

Recent expansions:

• Georgia (as of July 2024) now allows NPs/PAs to prescribe even Schedule II controlled substances with physician delegation—a significant expansion

Klarity Health works with appropriately licensed providers in each state we serve, ensuring you receive care from qualified clinicians operating within their legal scope of practice.

Who Qualifies for Telehealth GLP-1 Prescriptions?

Reputable telehealth providers don’t prescribe weight-loss medications to everyone who asks. Clinical eligibility criteria ensure these powerful medications go to patients who truly need them and can use them safely.

Standard Medical Criteria

To qualify for GLP-1 weight-loss medications, you typically need:

Body Mass Index (BMI) of:

• ≥30 (obesity), OR
• ≥27 with at least one weight-related health condition such as:
• Type 2 diabetes
• High blood pressure
• High cholesterol
• Sleep apnea
• Cardiovascular disease

Evidence of lifestyle modification attempts:

• Most providers require documentation that you’ve tried diet and exercise modifications before starting medication

No contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Current pregnancy or plans to become pregnant
• History of severe pancreatitis
• Active gallbladder disease
• Severe gastroparesis or other gastrointestinal disorders

What to Expect During Your Telehealth Evaluation

A legitimate telehealth consultation for weight-loss medication should include:

1. Comprehensive medical history review covering current medications, allergies, past medical conditions, and family history
2. Weight and vital signs verification (typically self-reported with photo documentation)
3. Discussion of treatment goals and realistic expectations
4. Review of potential side effects including nausea, vomiting, diarrhea, and rarer serious risks
5. Lifestyle counseling about diet, exercise, and behavioral modifications
6. Informed consent documenting that you understand the risks, benefits, and alternatives
7. Treatment plan outlining medication dosing, titration schedule, and follow-up intervals

States like New Jersey and Virginia have codified these elements into law, requiring providers to document each component. Even in states without specific mandates, this comprehensive approach represents the standard of care.

Understanding the Three Main GLP-1 Weight-Loss Medications

Wegovy (Semaglutide 2.4mg)

FDA Approval: Approved specifically for chronic weight management (2021)

Who it’s for: Adults with BMI ≥30 or ≥27 with weight-related conditions

How it works: Once-weekly injection that mimics GLP-1 hormone to reduce appetite and slow stomach emptying

Typical results: Average weight loss of 15-20% of body weight over 68 weeks when combined with lifestyle changes

Telehealth considerations: Fully approved for obesity treatment; no off-label concerns

Ozempic (Semaglutide 0.5-1mg)

FDA Approval: Approved for Type 2 diabetes management (2017)

Off-label use: Widely prescribed for weight loss due to same active ingredient as Wegovy, just at lower doses

Who it’s for: Patients with Type 2 diabetes; sometimes prescribed off-label for weight loss when Wegovy is unavailable

Telehealth considerations: Providers must document off-label rationale and obtain informed consent when prescribing for weight loss in non-diabetic patients

Important note: Do not use Ozempic if you’re already taking Wegovy—they contain the same active ingredient

Mounjaro (Tirzepatide) / Zepbound

FDA Approval: Mounjaro approved for Type 2 diabetes (2022); Zepbound approved for obesity (2023)

How it works: Dual-action medication that activates both GLP-1 and GIP receptors for enhanced weight loss

Typical results: Average weight loss of 20-25% of body weight in clinical trials—higher than semaglutide

Telehealth considerations: Newer medication with robust evidence; prescribed on-label when using Zepbound branding for obesity

The Truth About Compounded Semaglutide

You may have seen online advertisements for ‘compounded semaglutide’ at much lower prices than brand-name Wegovy or Ozempic. Here’s what you need to know:

FDA Crackdown in 2025

In May 2025, the FDA effectively banned routine compounding of semaglutide for weight loss after declaring the Wegovy shortage resolved. This decision had major impacts:

• Telehealth companies offering compounded versions had to halt programs
• Some providers laid off staff (e.g., Hims & Hers cut 4% of workforce)
• State pharmacy boards increased inspections to ensure compliance

Why the FDA Acted

Compounded medications bypass normal FDA safety and efficacy testing. Concerns included:

• Variable potency between batches
• Contamination risks
• Lack of proper sterility testing
• Patient confusion about dosing

Current Status

As of late 2025, legitimate telehealth providers prescribe only FDA-approved brand-name medications (Wegovy, Ozempic, Mounjaro, Zepbound). If a service offers suspiciously cheap ‘semaglutide’ without specifying the brand, it’s a red flag.

How to Identify Safe, Legitimate Telehealth Providers

The popularity of GLP-1 medications has unfortunately attracted some questionable operators. Here’s how to protect yourself:

Green Flags: Signs of a Reputable Service

✅ Requires comprehensive medical evaluation including detailed health history questionnaire

✅ Uses licensed, credentialed providers with transparent information about their qualifications

✅ Prescribes only FDA-approved medications from licensed U.S. pharmacies

✅ Schedules regular follow-up appointments to monitor progress and side effects

✅ Provides clear pricing upfront, including medication costs and consultation fees

✅ Accepts insurance when coverage is available (though many plans still don’t cover weight-loss medications)

✅ Discusses lifestyle modifications alongside medication—not just pills

✅ Has a physical address and clear contact information

Klarity Health embodies these principles with transparent pricing, provider availability across multiple states, acceptance of both insurance and cash pay, and a commitment to comprehensive, ongoing care.

Red Flags: Warning Signs to Avoid

🚩 Guarantees you’ll get a prescription before evaluating your medical history

🚩 Skips video consultation or relies only on a brief questionnaire

🚩 Offers ‘compounded’ or overseas versions of brand-name drugs

🚩 No mention of side effects or contraindications during the consultation

🚩 No follow-up appointments scheduled or monitoring plan

🚩 Provider credentials unclear or not licensed in your state

🚩 Pressure tactics to start treatment immediately

🚩 Vague about medication source or pharmacy location

If you encounter any of these red flags, look for a different provider. Your safety is too important to compromise.

What About Insurance Coverage?

One of the biggest barriers to GLP-1 weight-loss medications isn’t legal—it’s financial. These medications can cost $900-$1,500 per month without insurance.

Insurance Coverage Landscape

Medicare:

• Currently does not cover medications prescribed solely for weight loss
• Does cover these medications when prescribed for Type 2 diabetes (e.g., Ozempic, Mounjaro)
• Advocacy efforts ongoing to change this policy

Private Insurance:

• Coverage varies widely by plan
• Some employers specifically exclude weight-loss medications
• Others cover with prior authorization (requiring documentation of BMI, failed lifestyle modifications, etc.)
• Copays typically $25-$500/month when covered

Medicaid:

• Varies by state; some states cover, others don’t
• Often requires prior authorization and step therapy

The Klarity Health Advantage

Klarity Health accepts both insurance and cash pay, giving you flexibility regardless of your coverage situation. Our transparent pricing means you’ll know costs upfront, and our team can help navigate insurance authorization processes when coverage is available.

For patients paying cash, we work to keep costs as affordable as possible while maintaining the highest standards of medical care and using only FDA-approved medications from licensed pharmacies.

Privacy Considerations for Telehealth Weight-Loss Treatment

Weight and health information is deeply personal. When choosing a telehealth provider, understand how your data is protected.

Federal HIPAA Protections

All healthcare providers—including telehealth services—must comply with HIPAA (Health Insurance Portability and Accountability Act) privacy rules. This means:

• Your medical information must be encrypted during transmission
• Providers can’t share your health data without your permission
• You have the right to access your own medical records
• Security measures must protect against data breaches

State Privacy Laws

Some states have enacted additional privacy protections beyond HIPAA:

Washington’s My Health My Data Act (2023):

• Adds extra safeguards for health data collected by consumer apps and services
• Particularly relevant for telehealth platforms that collect sensitive weight/health information
• Requires explicit consent for data collection and use

California Consumer Privacy Act (CCPA):

• Gives California residents rights to know what personal data is collected
• Right to request deletion of data
• Applies to some telehealth platforms beyond traditional HIPAA-covered entities

What to Ask Your Telehealth Provider

Before sharing sensitive health information, ask:

• Is your platform HIPAA-compliant?
• How is my video consultation encrypted?
• Who has access to my medical records?
• How long do you retain my health data?
• Can I request deletion of my account and data?

Reputable providers will have clear, transparent answers to these questions.

The Future of Telehealth for Weight Management

Telehealth access to weight-loss medications is not a temporary pandemic-era convenience—it’s becoming the standard of care.

Why Telehealth Works for Obesity Treatment

Research shows that telehealth delivery of weight management programs can be equally effective to in-person care when properly structured:

• Regular virtual check-ins increase accountability
• Eliminates transportation barriers for patients with mobility challenges
• Enables more frequent monitoring (vs. quarterly in-person visits)
• Integrates well with connected devices (smart scales, fitness trackers)
• Reduces stigma some patients feel about in-person weight discussions

What’s Coming Next

Expanded medication options:

• New GLP-1 and dual-agonist medications in development
• Oral versions of semaglutide (currently available for diabetes, obesity formulation in trials)
• Combination therapies showing even greater weight loss

Regulatory streamlining:

• Interstate licensure compacts making it easier for providers to treat patients nationwide
• Likely continued or permanent telehealth flexibilities from federal government
• More states granting full practice authority to Nurse Practitioners

Integration with digital health:

• AI-assisted monitoring of side effects and progress
• Automated medication reminders and injection training
• Connected devices for real-time vital signs monitoring

Insurance expansion:

• Growing recognition of obesity as a chronic disease requiring medical treatment
• Advocacy efforts to expand Medicare coverage
• More employers adding weight-loss medication coverage

Frequently Asked Questions

Can I switch from in-person care to telehealth while already on medication?

Yes. If you’re currently receiving GLP-1 medications through traditional in-person visits, you can often transition to telehealth for ongoing management. You’ll need to establish care with a new provider (via video consultation), who will review your treatment history and continue your prescription if clinically appropriate. Make sure to request your medical records from your previous provider to share with your new telehealth clinician.

What if I travel or move to another state?

Telehealth providers must be licensed in the state where you are physically located during the consultation and when receiving care. If you move permanently, you’ll need to ensure your provider is licensed in your new state (or transfer to a provider who is). For temporary travel, check with your provider—some can maintain care if it’s a short trip, while others may require you to be in your home state for appointments.

How quickly can I get started?

With telehealth, the timeline is typically:

• Same-day or next-day appointment availability
• 24-48 hours for prescription to be sent to pharmacy after approval
• 3-7 days for medication to be in stock and ready for pickup (though shortages can extend this)

Total time from first inquiry to starting medication is often under a week with a telehealth provider versus several weeks to get an appointment with a traditional weight-loss clinic.

What happens if I experience side effects?

Your telehealth provider should have a clear protocol for managing side effects:

• Messaging portal for non-urgent questions between appointments
• Phone support for more urgent concerns
• Guidance on when to seek emergency care (e.g., severe abdominal pain, signs of pancreatitis)
• Dose adjustments if side effects are intolerable
• Discontinuation plan if medication isn’t appropriate for you

The most common side effects (nausea, diarrhea, constipation) usually improve over time and can often be managed with dietary modifications and slower dose titration.

Are there any age restrictions?

Most GLP-1 medications are FDA-approved for adults 18 and older. Some (like Wegovy) now have approvals for adolescents age 12+ with obesity, but this typically requires in-person pediatric obesity specialty care rather than telehealth. If you’re over 75, providers may require additional evaluation to ensure safety, but age alone is not a contraindication.

Can I get these medications if I have Type 1 diabetes?

No. GLP-1 agonists are not approved for Type 1 diabetes and are generally contraindicated. They’re designed for Type 2 diabetes (where the body still produces some insulin) and obesity. If you have Type 1 diabetes and weight concerns, work with your endocrinologist to explore other options.

Taking the Next Step

If you’re struggling with obesity or weight-related health conditions, GLP-1 medications prescribed through telehealth may be a valuable tool in your journey toward better health. The key is choosing a provider that prioritizes your safety, follows evidence-based protocols, and supports you with comprehensive care—not just a prescription.

What You Should Do Now

1. Verify your state’s requirements using the state-by-state table in this guide
2. Calculate your BMI to see if you meet basic eligibility criteria
3. Review your medical history for any contraindications
4. Research telehealth providers in your state, looking for the green flags outlined above
5. Check your insurance to understand potential coverage and costs
6. Schedule a consultation with a reputable provider to discuss your individual situation

How Klarity Health Can Help

At Klarity Health, we make accessing evidence-based weight management care simple and affordable:

✓ Licensed providers in multiple states with expertise in obesity medicine
✓ Same-day or next-day appointments available
✓ Transparent pricing with both insurance and cash pay options
✓ Comprehensive care including initial evaluation, medication management, lifestyle counseling, and ongoing monitoring
✓ FDA-approved medications only from licensed U.S. pharmacies
✓ Flexible follow-up via video or messaging to fit your schedule

We believe quality healthcare should be accessible to everyone, regardless of where you live or your ability to take time off work for in-person appointments.

Ready to take the first step? Visit Klarity Health to schedule your confidential consultation and see if GLP-1 medication therapy is right for you.

Research & Sources

This guide was compiled using the most current regulatory information and clinical guidelines available as of December 17, 2025. Below are the primary sources used:

1. DEA Announcement (Nov 2024) – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (www.dea.gov) – Official government release confirming federal telehealth rule status through December 31, 2025.

2. Axios News (Nov 2024) – COVID-era telehealth prescribing extended (www.axios.com) – News coverage of DEA extension with analysis of implications for controlled substance prescribing.

3. McDermott Will & Emery Legal Analysis (Nov 2024) – ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025’ (www.mwe.com) – Expert legal analysis of DEA regulations, proposals, and the distinction between controlled and non-controlled medications in telehealth context.

4. Goodwin Procter Law Alert (Mar 2024) – ‘The Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (www.goodwinlaw.com) – Comprehensive analysis of state-specific requirements in Florida, New Jersey, Virginia, and other jurisdictions for prescribing weight-loss medications.

5. Reuters (May 2025) – ‘Hims to cut 4% of workforce amid ban on weight-loss drug copies’ (www.reuters.com) – Coverage of FDA’s decision to end emergency allowance for compounded semaglutide and industry impact.

Additional sources consulted include state medical board regulations, the Texas Medical Board prescribing guidelines, U.S. Senate legislative records (TREATS Act), Nextech’s state-by-state semaglutide law compilation, and professional nursing organizations’ practice authority updates. All information has been verified as current through December 2025.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Telehealth regulations and medication approvals can change. Always consult with a licensed healthcare provider about your individual health needs and treatment options. Klarity Health providers will evaluate your specific situation and determine if GLP-1 medication therapy is appropriate for you based on current medical guidelines and your state’s regulations.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid